Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has developed a new small-molecule oral compound for the treatment of Parkinson’s disease, FHND-1002, which demonstrated neuronal protection in models of neurodegenerative diseases and neuron trauma.